Journal
BREAST CARE
Volume 14, Issue 2, Pages 111-116Publisher
KARGER
DOI: 10.1159/000497233
Keywords
Adjuvant treatment; Aromatase inhibitors; Breast cancer; Chemotherapy; Endocrine therapy; Quality of life; Side effects; Toxicity
Categories
Ask authors/readers for more resources
Background: Chronic treatment sequelae may substantially reduce the long-term quality of life in breast cancer survivors. Methods: We report a comprehensive Web-based survey on the presence of long-term side effects of adjuvant anti-breast cancer therapy in 1,506 patients who had been diagnosed with primary breast cancer at least 1 year before. Results: Fatigue, depression, depressive mood, concentration deficit, pain, changes of mucosa and skin appendages, as well as symptoms of peripheral neuropathy were the most prevalent reported complaints. Chemotherapies-taxane-based regimens in particular-were associated with increased rates of long-term symptoms, including persistent peripheral neuropathy. Overall, the data show a substantial prevalence of a wide variety of potentially treatment-associated symptoms over a protracted time frame after the diagnosis of breast cancer. The burden of symptoms was high for fatigue, depression, sleep disturbances, pain, and peripheral neuropathic symptoms. Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence. (c) 2019 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available